| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DMPK |
| Uniprot No | Q09013 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-629aa |
| 氨基酸序列 | MSAEVRLRRLQQLVLDPGFLGLEPLLDLLLGVHQELGASELAQDKYVADFLQWAEPIVVRLKEVRLQRDDFEILKVIGRGAFSEVAVVKMKQTGQVYAMKIMNKWDMLKRGEVSCFREERDVLVNGDRRWITQLHFAFQDENYLYLVMEYYVGGDLLTLLSKFGERIPAEMARFYLAEIVMAIDSVHRLGYVHRDIKPDNILLDRCGHIRLADFGSCLKLRADGTVRSLVAVGTPDYLSPEILQAVGGGPGTGSYGPECDWWALGVFAYEMFYGQTPFYADSTAETYGKIVHYKEHLSLPLVDEGVPEEARDFIQRLLCPPETRLGRGGAGDFRTHPFFFGLDWDGLRDSVPPFTPDFEGATDTCNFDLVEDGLTAMVSGGGETLSDIREGAPLGVHLPFVGYSYSCMALRDSEVPGPTPMELEAEQLLEPHVQAPSLEPSVSPQDETAEVAVPAAVPAAEAEAEVTLRELQEALEEEVLTRQSLSREMEAIRTDNQNFASQLREAEARNRDLEAHVRQLQERMELLQAEGATAVTGVPSPRATDPPSHLDGPPAVAVGQCPLVGPGPMHRRHLLLPARVPRPGLSEALSLLLFAVVLSRAAALGCIGLVAHAGQLTAVWRRPGAARAP |
| 预测分子量 | 69,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于DMPK(药物代谢与药代动力学)与重组蛋白研究的示例参考文献(内容为模拟概括，非真实文献)：
1. **"Expression and functional characterization of recombinant human cytochrome P450 enzymes for drug metabolism studies"**
- 作者：Guengerich FP, et al.
- 摘要：研究通过重组技术表达人源细胞色素P450酶(如CYP3A4、CYP2D6)，验证其在体外药物代谢中的活性，为药物相互作用和代谢稳定性评估提供标准化工具。
2. **"Recombinant drug transporters in DMPK: Applications in predicting intestinal absorption and biliary excretion"**
- 作者：Giacomini KM, et al.
- 摘要：利用重组表达的转运蛋白(如P-gp、BCRP)，建立体外模型评估药物在肠道吸收和肝胆排泄中的转运机制，提升药代动力学预测准确性。
3. **"In vitro models combining recombinant enzymes and hepatocytes for hepatic clearance prediction"**
- 作者：Obach RS, et al.
- 摘要：提出将重组代谢酶(CYP、UGT)与原代肝细胞模型结合，模拟肝脏代谢过程，优化药物清除率及代谢途径分析的实验策略。
4. **"Computational and experimental approaches to study protein-drug binding using recombinant albumin"**
- 作者：Rowland M, et al.
- 摘要：通过重组人血清蛋白(rHSA)结合分子对接技术，量化药物-蛋白结合率，阐释其对药物分布和半衰期的影响机制。
(注：以上文献信息为示例，实际文献需通过学术数据库检索确认。)
**Background of DMPK Recombinant Proteins**
DMPK (myotonic dystrophy protein kinase) is a serine-threonine kinase encoded by the *DMPK* gene, primarily expressed in skeletal and cardiac muscles. It plays a critical role in maintaining cellular homeostasis, including regulating ion channel function, RNA splicing, and muscle cell differentiation. Mutations in the *DMPK* gene, particularly CTG repeat expansions, are linked to myotonic dystrophy type 1 (DM1), a multisystemic disorder characterized by muscle weakness, myotonia, and cardiac abnormalities.
Recombinant DMPK proteins are engineered using biotechnological methods to produce purified, functional forms of the kinase for research and therapeutic applications. These proteins are generated by cloning the *DMPK* gene into expression vectors (e.g., bacterial, insect, or mammalian systems), followed by protein expression, purification, and validation. Recombinant DMPK enables detailed studies of its enzymatic activity, substrate interactions, and structural properties, which are essential for understanding DM1 pathogenesis and identifying potential drug targets.
In drug discovery, recombinant DMPK serves as a tool for high-throughput screening of kinase inhibitors or modulators to correct aberrant cellular pathways in DM1. Additionally, it aids in elucidating the molecular mechanisms of CTG repeat toxicity and testing antisense oligonucleotides or small molecules aimed at reducing toxic RNA aggregates. Challenges in developing recombinant DMPK include ensuring proper post-translational modifications (critical for kinase activity) and mimicking native conformational states. Advances in expression systems and structural biology continue to enhance the utility of these proteins, bridging gaps between basic research and clinical interventions for neuromuscular disorders.
×
